Novo Nordisk Gains as EU Panel Backs Hemophilia A Antibody, Orbis Deal Adds Oral Pipeline

Novo Nordisk shares gained 3.6% after EU regulators backed hemophilia A drug Denecimig, alongside a $1.4 billion oral-drug pact with Orbis Medicines.

Shares of Novo Nordisk advanced on Thursday after the European Medicines Agency's human medicines committee threw its weight behind a new hemophilia A treatment, while a separate licensing pact worth up to $1.4 billion signaled the Danish drugmaker's push into oral therapies.

The stock climbed 3.6% to EUR 37.77, pulling further away from its 52-week low of EUR 30.25 — a premium of roughly 25%. The CHMP's endorsement of FREHEMGO (Denecimig) covers adults and children with hemophilia A, irrespective of whether they carry inhibitors, broadening the addressable patient pool across Europe.

Switch Data Published Alongside CHMP Opinion

The positive opinion sets the stage for a final marketing authorization decision by the European Commission. First launches are targeted for the fourth quarter of 2026, with a wider roll-out across additional European countries expected the following year. In the United States, a corresponding application has been on file with the FDA since September 2025.

Timing of the regulatory milestone coincided with the publication of detailed clinical data in the Journal of Thrombosis and Haemostasis. In the trial, adolescents and adults switched directly from the established standard of care, Emicizumab, to the new antibody. No unexpected safety signals emerged, and the transition required neither a washout period nor a separate loading dose. Participants self-administered the drug via a single-use prefilled pen, which most preferred over conventional syringe systems. Dosing can be spaced flexibly, from weekly injections to once-monthly administration.

CEO Mike Doustdar pointed to sustained bleed protection and simplified day-to-day handling as key differentiators. Because patients with inherited bleeding disorders depend on lifelong prophylactic injections, reliable protection and adaptable schedules are central to acceptance. Analysts view the solid switch data as an important prerequisite for challenging entrenched treatment standards.

Rebranding and a $1.4 Billion Oral-Drug Alliance

The regulatory progress lands at a busy moment for the company, which has been overhauling its market presence. Since Monday it has operated under the unified name Novo, accompanied by a repositioning under the slogan "Lasting Health Starts Now" and an updated cultural framework, "The Novo Way," aimed at sharpening speed and execution in global competition.

Alongside the hemophilia news, Novo Nordisk struck a broad research collaboration with biotech firm Orbis Medicines. The agreement provides for milestone payments, royalties and equity participation totaling up to $1.4 billion, and focuses on orally administered macrocyclic compounds for cardiometabolic indications. The deal underscores management's ambition to build a tablet-based portfolio for the longer term.

Milan Congress and Mixed Pipeline Signals

Further scientific catalysts lie ahead. At the annual meeting of the European Association for the Study of Diabetes (EASD), running from September 28 to October 2 in Milan, the company will present new data, including clinical results and real-world use figures for the Wegovy pill as well as updates on next-generation amylin-based cardiometabolic candidates.

Not every recent development has gone Novo's way. On September 7, management halted two studies of the cardiovascular candidate Ziltivekimab after an interim analysis indicated the trials would likely miss their expected endpoints, a setback for diversification efforts beyond diabetes and obesity. More encouragingly, on September 11 the company reported that Wegovy won approval in China as the first GLP-1 receptor agonist cleared to treat metabolic steatotic hepatitis (MASH).

Even after Thursday's gain, the shares remain well below their 52-week high of EUR 54.86.